A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Clinical Trials, High Risk Prostate Cancer, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05787587
Phase: Phase 1
Trial Summary: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): IDEAYA Biosciences
Acronym:

Pin It on Pinterest